PLENARY KEYNOTE SESSIONS
Tuesday, March 26
8:00 am Chairperson's Remarks
Kevin Davies, PhD, Executive Editor, The CRISPR Journal; Author, Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing
8:05 am Plenary Keynote Introduction
Damian Verdnik, PhD, Director, Diagnostics, Dx PMO, Invetech
8:15 am Convergence of Artificial Intelligence and Precision Oncology
Douglas Flora, MD, Executive Medical Director, Oncology Services, St. Elizabeth Healthcare; Editor-in-Chief, AI in Precision Oncology Journal
Kevin Davies, PhD, Executive Editor, The CRISPR Journal; Author, Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing
Artificial Intelligence (AI) is exhibiting immense power to transform the practice of science and medicine, from genome analysis and drug discovery to health data and the practice of medicine. Nowhere is this more evident than in the field of oncology. In 2019, clinical oncologist Douglas Flora read Deep Medicine, the best-selling book by Scripps Research President Eric Topol. He was immediately convinced of the power of AI to transform the work of his medical staff—and the lives of his patients. Last year, Dr. Flora launched a new journal, AI in Precision Oncology, to disseminate stories and examples of the transformative potential of AI in oncology. In this fireside chat, Dr. Flora will share his AI epiphany and offer real-world examples of how AI is already changing the practice of medicine—at his organization (St. Elizabeth Healthcare) and beyond.
8:45 am PANEL DISCUSSION: AI and Genomics Come Together
PANEL MODERATOR:
Kevin Davies, PhD, Executive Editor, The CRISPR Journal; Author, Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing
Artificial intelligence (AI) promises to enable the analysis of trillions of genomic, molecular, clinical, and epidemiological data, offering unprecedented insights into health and disease, the development of drugs and diagnostics, and empowering precision medicine. Our distinguished panel will review the opportunities, challenges, and innovations in applying emerging AI tools to biological data, and their potential to revolutionize drug development, diagnostics, and precision medicine.
PANELISTS:
Kari Stefansson, MD, PhD, CEO, deCODE genetics
Atul Butte, MD, PhD, Distinguished Professor and Institute Director, University of California
Pankaj Vats, PhD, Senior Bioinformatics/Genomics Scientist, NVIDIA
Jonathan M. Carlson, PhD, General Manager, Life Sciences, Microsoft Health Futures
4:10 pm Chairperson's Remarks
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University
4:15 pm FIRESIDE CHAT: Artificial Intelligence Innovation for Precision Medicine
Eric Topol, MD, Founder and Director, Scripps Research Translational Institute; Executive Vice President and Professor, Scripps Research
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University
A visionary at the intersection of medicine and technology, Dr. Eric Topol articulates the big picture for radical improvement in healthcare through personalized and data-driven medicine. Eric published three books, over 1,200 peer reviewed publications, and provides his reasoned perspective on medical AI frequently on social media. We will discuss his views on the current state of precision medicine and artificial intelligence, including generative AI in medicine, diagnostics, and clinical trials.
4:45 pm PANEL DISCUSSION: AI in Precision Medicine: Innovation and Growth Opportunities
PANEL MODERATOR:
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University
The convergence of artificial intelligence (AI) and precision medicine promises to revolutionize health care. Generative AI, machine learning, and sophisticated computational power promise to enable clinical decision support and diagnostics, support drug development, and optimize personalized medicine.
PANELISTS:
Chris M. Hartshorn, PhD, Chief, Digital & Mobile Technologies Section—CTSA Program, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)
Michael Pellini, MD, General Partner, S32
Charity Williams, Partner, Cooley LLP
Wednesday, March 27
8:00 am Chairperson's Remarks
Edward Abrahams, PhD, President, Personalized Medicine Coalition
8:05 am Plenary Keynote Introduction
Paul Beresford, Vice President and General Manager, CDx, Agilent Technologies
8:15 am PANEL DISCUSSION: The State of Innovation in Diagnostic Testing for Personalized Medicine
PANEL MODERATOR:
Edward Abrahams, PhD, President, Personalized Medicine Coalition
Integrating diagnostics into clinical care faces numerous challenges, including regulatory, reimbursement, and clinical adoption among others, before the promise of personalized medicine can be realized. This panel, with support from the Personalized Medicine Coalition, will consider these barriers and propose solutions to overcome them.
PANELISTS:
Paul Beresford, Vice President and General Manager, CDx, Agilent Technologies
Peter Bach, MD, CMO, Delfi Diagnostics
Christopher Conn, PhD, Global Director, Clinical Biomarkers & Diagnostics, Diagnostics Strategy Lead, Amgen
Jeffrey Venstrom, MD, CMO, GRAIL
Justin Odegaard, MD, PhD, Vice President, Clinical Development, Guardant Health